BioSpace News Archive

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the results from a Phase 2b clinical trial evaluating the efficacy, tolerability, and safety of islatravir (MK-8591), the company’s investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), for the treatment of HIV-1.

Today ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced that data from the phase III TANGO study showed that the 2-drug regimen (2DR) of Dovato▼ (dolutegravir/lamivudine) has similar efficacy to a tenofovir alafenamide fumarate (TAF)-containing regimen of at least three drugs in virally supressed and stable adults with HIV-1

the Chief Veterinary Officer (CVO) for Canada, Dr. Jaspinder Komal, issued the following statement about an important step to communicate our preparedness for African swine fever (ASF)

The 12 step recovery principles help those struggling with addiction develop a healthy self and a connectedness to a Higher Power.

Supporting World Hepatitis Day (WHD) July 28

The National Kidney Foundation named today Dr. Charuhas Thakar as the new editor-in-chief of its journal Advances in Chronic Kidney Disease (ACKD).

Allscripts Healthcare Solutions, Inc. (Nasdaq:MDRX) will report its financial results for the three months ended June 30, 2019, after the close of stock market hours on Thursday, August 8, 2019

Sandata Technologies, LLC, the leading provider of Electronic Visit Verification (“EVV”) and home health technology solutions, today announced it has secured a significant growth equity investment from Accel-KKR, a leading Silicon Valley-based investment firm.

The Sheikh Zayed Institute for Pediatric Surgical Innovation at Children’s National Health System announces its 7th Annual Pediatric Device Innovation Symposium is slated for Sunday, Sept. 22 in Boston, Mass., featuring a $150K medical device competition focused on innovations for neonatal and NICU care.

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced Week 96 results from its phase III GEMINI 1 & 2 studies,